drugset / Trial / NCT02361502
MIrabegron With oveRACtive bLadder Symptoms in mEn
RandomizedParallel-groupDouble-blindTreatment
Summary
The proportion of male patients who participated in the phase III study of mirabegron was about 28% and the data on the efficacy and safety of mirabegron in Korean male OAB patients have limits. For this reason, this study will assess the efficacy and safety of mirabegron in Korean male OAB patients.
Timeline
- Start
- 2015-02
- Primary completion
- 2016-01
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirabegron | Other / unclassified | 50 mg | — |